|
1
|
Ni WF, Zhou KL, Zhang HJ, Chen YT, Hu XL, Cai WT, Wang XY. Functions and mechanisms of cytosolic phospholipase A 2 in central nervous system trauma. Neural Regen Res 2023; 18:258-266. [PMID: 35900400 PMCID: PMC9396495 DOI: 10.4103/1673-5374.346460] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
|
2
|
Parfenov AI, Akhmadullina OV, Belostotsky NI, Sabelnikova EA, Novikov AA, Bykova SV, Dbar SR. Enteropathy with impaired membrane digestion and the prospects for cytoprotective therapy. TERAPEVT ARKH 2021; 93:129-137. [DOI: 10.26442/00403660.2021.02.200602] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Accepted: 04/05/2021] [Indexed: 12/24/2022]
Abstract
The article describes enteropathy with impaired membrane digestion (EIMD) as a new nosological form. The main clinical manifestation of EIMD is the poor tolerance of food products, in particular carbohydrates and a decrease in the activity of membrane enzymes, in particular, carbohydrates, in the mucous membrane of the small intestine. The cause of the disease can be acute intestinal infections, viruses, drugs and other agents that damage the small intestine. The pathophysiology, clinical picture and diagnosis of EIMD are described. The basis of therapy is rebamipide, which has the ability to reduce the symptoms of carbohydrate intolerance and increase the activity of disaccharidases.
Collapse
|